Nomura Holdings Inc (NMR) Stock Price Today
Aura AI Summary
Key Stats
- $27.88BMarket Cap
- -Volume
- FinancialsSector
- $9.6652W High
- $6.3052W Low
- -Typical Hold Time
- -Enterprise Value
- 3.35%Div Yield
- -Trading Activity
Track Nomura Holdings Inc (NMR) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Nomura Holdings Inc has traded between a low of $6.3 and a high of $9.66, highlighting its annual price range. Buy and sell Nomura Holdings Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Most Recent News
AI use in cybersecurity jumps to 78% in 2026, but governance and failures lag behind.
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.